Astellas, Sony Team on Novel ADC Platform for Oncology
BIOMARKER
1. Astellas Pharma and Sony Corporation are partnering to develop a novel antibody-drug conjugate (ADC) platform for oncology therapeutics.
2. Sony's biotech R&D arm will provide a unique polymeric material called Kiravia Backbone as the linker for the ADC.
3. The linker plays a crucial role in determining the effectiveness and side effects of ADCs.
4. Astellas believes that Sony's polymer design will enhance the delivery of the anti-cancer payload to targeted malignant cells, improving efficacy and reducing off-target effects.
5. Feasibility studies in human cancer cells were conducted last summer, leading to the current collaboration.
6. Astellas already has a successful partnered ADC on the market called Padcev, developed with Seagen for urothelial cancer treatment.
7. The ADC space has been active recently, with Pfizer acquiring Seagen for $43 billion and AstraZeneca striking deals for ADCs.
8. The collaboration between Astellas and Sony will focus on developing a novel ADC platform, with non-clinical studies planned.
9. Astellas recently announced its acquisition of Iveric Bio to strengthen its focus on blindness and regeneration.
10. Astellas' annual revenue was slightly down in 2022, and the company is expanding its oncology portfolio with strategic partnerships and acquisitions.